Amgen shares extended their rally after CEO Bob Bradway told CNBC's Jim Cramer that new late-stage data showed Repatha cut first heart attack risk by 36% and major cardiovascular events by 25%. Bradway said most heart attacks stem from modifiable risks like high LDL, positioning Amgen at the forefront of early heart disease prevention.